1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Antibiotics Partnering Terms and Agreements 2010 to 2017

Global Antibiotics Partnering Terms and Agreements 2010 to 2017

  • April 2017
  • -
  • Currentpartnering
  • -
  • 222 pages

Summary

Table of Contents

Search Inside

Summary
The Global Antibiotics Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the antibiotic partnering deals and agreements entered into by the worlds leading healthcare companies

Description
The Global Antibiotics Partnering Terms and Agreements 2010 to 2017 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

- Trends in antibiotics partnering deals
- Disclosed headlines, upfronts, milestones and royalties by stage of development
- Antibiotics partnering contract documents
- Top antibiotics deals by value

The Global Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:
- Antibiotics
- Aminoglycosides
- Cephalosporin
- Clindamycin
- Macrolides
- Penicillin
- Quinolones
- Sulfonamides
- Tetracycline

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 200 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What are the precise rights granted or optioned?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of antibiotics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibiotics deals since 2010. Deals are listed by headline value, signed by big pharma, most active antibiotics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotics dealmaking with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010. The chapter is organized by specific antibiotics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.

Report scope
Global Antibiotics Partnering Terms and Agreements 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.

Global Antibiotics Partnering Terms and Agreements 2010 to 2017 includes:
- Trends in antibiotics dealmaking in the biopharma industry since 2010
- Analysis of antibiotics deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life antibiotics deals
- Access to over 200 antibiotics deal records and contract documents where available
- The leading antibody deals by value since 2010
- Most active antibiotics dealmakers since 2010
- The leading antibiotics partnering resources

In Global Antibiotics Partnering Terms and Agreements 2010 to 2017, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Global Antibiotics Partnering Terms and Agreements 2010 to 2017 provides the reader with the following key benefits:
- In-depth understanding of antibiotics deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of antibiotics agreements with numerous real life case studies
- Comprehensive access to over 200 antibiotics deals entered into by the world’s biopharma companies, together with real world clause examples and contracts where available
- Full listing of antibiotics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
- Identify leading antibiotics deals by value since 2010
- Identify the most active antibiotics dealmakers since 2010
- Detailed access to actual antibiotics contracts enter into by the leading fifty big pharma and big biotech companies
- Insight into the terms included in a antibiotics agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Infectious Disease Drugs: The Chinese Market

Infectious Disease Drugs: The Chinese Market

  • $ 6650
  • Industry report
  • March 2017
  • by BCC Research

Use this report to: - Assess market dynamics of Chinese market for both communicable and - non-communicable infectious disease drugs, their opportunities and restraints. - Evaluate Chinese drug market ...

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

  • $ 4995
  • Industry report
  • January 2017
  • by GBI Research

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance Summary The antibacterial drug market covers ...

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

  • $ 4995
  • Industry report
  • March 2017
  • by GBI Research

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market Summary Respiratory complications are a ...


Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in the UK

  • April 2017
    11 pages
  • Anti-Infective  

    Point Of Care T...  

    Hospital  

  • United Kingdom  

View report >

Anti-Infective Market in the US - Forecast

  • April 2017
    4 pages
  • Anti-Infective  

  • United States  

View report >

Anti-Infective Market in Australia and the US - Forecast

  • April 2017
    8 pages
  • Anti-Infective  

    Meat  

  • Australia  

    United States  

    Europe  

View report >

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.